We are proud to complete this financing led by BVCF, a leading healthcare investor in China, and look forward to accelerating our work to bring revolutionary CAR-T cell therapy to HCC patients, and eventually to other cancer patients as well.
Zhi Yang, the managing partner of BVCF, "We are very excited to be involved in the evolution of CARsgen.
Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Weixin Xu and Davis Yang of BVCF will join the MicuRx board of directors.
We invest in companies with experienced management teams and sound strategic plans," said Zhi Yang, general partner at BVCF.